Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kv 11.1-Mab-PEG-TiO2 NPs
- Development stage
- Preclinical
- Lead developer
- AIRC Foundation for Cancer Research
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Kv 11.1-Mab-PEG-TiO2 NPs is a novel targeted nanoparticle delivery system designed for the treatment of pancreatic ductal adenocarcinoma (PDAC). The system utilizes titanium dioxide (TiO2) nanocrystals as a core, which are functionalized with dicarboxylic acid-terminated polyethylene glycol (PEG) linkers. These linkers are conjugated to monoclonal antibodies (Kv 11.1-Mab) specific to the Kv 11.1 potassium channel (also known as HERG or KCNH2). The Kv 11.1 channel is frequently overexpressed on the plasma membrane of PDAC cells, allowing the nanoparticles to selectively recognize and internalize into tumor cells. While traditional TiO2 nanoformulations can be toxic, this specific PEGylated and antibody-conjugated system is reported to be non-cytotoxic, offering a potential platform for photodynamic or sonodynamic cancer therapies.
- Other names
- anti-Kv 11.1 antibody-conjugated PEG-TiO2anti-Kv11.1 antibody-conjugated PEG-TiO2anti-Kv-11.1 antibody-conjugated PEG-TiO2Kv 11.1-Mab-PEG-TiO2 nanoparticlesKv11.1-Mab-PEG-TiO2 nanoparticlesKv-11.1-Mab-PEG-TiO2 nanoparticlesKv 11.1 monoclonal antibody + polyethylene glycol + titanium dioxide
02
Targets
KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on Kv 11.1-Mab-PEG-TiO2 NPs.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kv 11.1-Mab-PEG-TiO2 NPs.